Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Kara-Louise Royle"'
Autor:
Fiona Collinson, Kara-Louise Royle, Jayne Swain, Christy Ralph, Anthony Maraveyas, Tim Eisen, Paul Nathan, Robert Jones, David Meads, Tze Min Wah, Adam Martin, Janine Bestall, Christian Kelly-Morland, Christopher Linsley, Jamie Oughton, Kevin Chan, Elisavet Theodoulou, Gustavo Arias-Pinilla, Amy Kwan, Luis Daverede, Catherine Handforth, Sebastian Trainor, Abdulazeez Salawu, Christopher McCabe, Vicky Goh, David Buckley, Jenny Hewison, Walter Gregory, Peter Selby, Julia Brown, Janet Brown
Publikováno v:
Health Technology Assessment, Vol 28, Iss 45 (2024)
Background There is interest in using treatment breaks in oncology, to reduce toxicity without compromising efficacy. Trial design A Phase II/III multicentre, open-label, parallel-group, randomised controlled non-inferiority trial assessing treatment
Externí odkaz:
https://doaj.org/article/f262d31cdee84d25b7afd7439e0362e7
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-13 (2023)
Abstract Background Overall survival is the “gold standard” endpoint in cancer clinical trials. It plays a key role in determining the clinical- and cost-effectiveness of a new intervention and whether it is recommended for use in standard of car
Externí odkaz:
https://doaj.org/article/feb1a8274067465395fbf5561ed28cdd
Autor:
Roger Owen, Mark Cook, David Meads, David A Cairns, Christopher Parrish, Gordon Cook, Kwee Yong, Guy Pratt, Martin Kaiser, Karthik Ramasamy, Graham Jackson, Catherine Olivier, Amy Beth Coulson, Kara-Louise Royle, Anna Hockaday, Ruth de Tute, Bryony Dawkins, Mark Drayson, Jonathan Sive, Holger W Auner, Sergio Quezada, Lorna Barnard, Rhiannon Lambkin, Andrea Paterson, Mike Chapman, Rakesh Popat, Ceri Bygrave, Andrew Chantry, Samir Asher
Publikováno v:
BMJ Open, Vol 12, Iss 11 (2022)
Introduction Multiple myeloma is a plasma cell malignancy that accounts for 1%–2% of newly diagnosed cancers.At diagnosis, approximately 20% of patients can be identified, using cytogenetics, to have inferior survival (high-risk). Additionally, sta
Externí odkaz:
https://doaj.org/article/bf5f5424894a43a2927ade7759c778ff
Autor:
Kara-Louise Royle, David A. Cairns
Publikováno v:
Diagnostic and Prognostic Research, Vol 5, Iss 1, Pp 1-14 (2021)
Abstract Background The United Kingdom Myeloma Research Alliance (UK-MRA) Myeloma Risk Profile is a prognostic model for overall survival. It was trained and tested on clinical trial data, aiming to improve the stratification of transplant ineligible
Externí odkaz:
https://doaj.org/article/27852a26a0e24da687f61109434b7853
Autor:
Roger Owen, John Jones, David Meads, David A Cairns, Christopher Parrish, Gordon Cook, Neil Rabin, Matthew Jenner, Martin Kaiser, Kevin Boyd, Graham Jackson, Catherine Olivier, Amy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, Anna Hockaday, Jennifer Bird, Stella Bowcock, Ruth de Tute, Hayley Gardner, Bryony Dawkins, Rowena Henderson, Phillip Best, Bhuvan Kishore, Mark Drayson
Publikováno v:
BMJ Open, Vol 12, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/3d2818c0a21d4f5daf3843685e054b9c
Autor:
Janet E Brown, Kara-Louise Royle, Walter Gregory, Christy Ralph, Anthony Maraveyas, Omar Din, Timothy Eisen, Paul Nathan, Tom Powles, Richard Griffiths, Robert Jones, Naveen Vasudev, Matthew Wheater, Abdel Hamid, Tom Waddell, Rhona McMenemin, Poulam Patel, James Larkin, Guy Faust, Adam Martin, Jayne Swain, Janine Bestall, Christopher McCabe, David Meads, Vicky Goh, Tze Min Wah, Julia Brown, Jenny Hewison, Peter Selby, Fiona Collinson, Judith Carser, Gopalakrishnan Srinivasan, Fiona Thistlewaite, Ashraf Azzabi, Mark Beresford, David Farrugia, Marios Decatris, Carys Thomas, Joanna Gale, James McAleer, Alison Clayton, Ekaterini Boleti, Thomas Geldart, Santhanam Sundar, Jason Lester, Nachi Palaniappan, Mohan Hingorani, Khaliq Rehman, Mohammad Khan, Naveed Sarwar, Janine Graham, Alastair Thomson, Narayanan Srihari, Denise Sheehan, Rajaguru Srinivasan, Omar Khan, Andrew Stockdale Jane Worlding, Stergios Boussios, Nicholas Stuart, Carey MacDonald-Smith, Falalu Danwata, Duncan McLaren, Aravindhan Sundaramurthy, Anna Lydon, Sharon Beesley, Kathryn Lees, Mohini Varughese, Emma Gray, Angela Scott, Mark Baxter, Anna Mullard, Pasquale Innominato, Gaurav Kapur, Anil Kumar, Natalie Charnley, Caroline Manetta, Prabir Chakraborti, Prantik Das, Sarah Rudman, Henry Taylor, Christos Mikropoulos, Martin Highley, Dakshinamoorthy Muthukumar, Anjali Zarkar, Roy Vergis, Seshadri Sriprasad, Patryk Brulinski, Amanda Clarke, Richard Osbourne, Melanie Harvey, Renata Dega, Geoffrey Sparrow, Urmila Barthakur, Erica Beaumont, Agnieszka Michael, Emilio Porfiri, Faisal Azam, Ravi Kodavtiganti
Publikováno v:
STAR Investigators, Brown, J E, Royle, K-L, Gregory, W, Ralph, C, Maraveyas, A, Din, O, Eisen, T, Nathan, P, Powles, T, Griffiths, R, Jones, R, Vasudev, N, Wheater, M, Hamid, A, Waddell, T, McMenemin, R, Patel, P, Larkin, J, Faust, G, Martin, A, Swain, J, Bestall, J, McCabe, C, Meads, D, Goh, V, Min Wah, T, Brown, J, Hewison, J, Selby, P & Collinson, F 2023, ' Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial ', Lancet Oncology, vol. 24, no. 3, pp. 213-227 . https://doi.org/10.1016/S1470-2045(22)00793-8
Temporary drug treatment cessation might alleviate toxicity without substantially compromising efficacy in patients with cancer. We aimed to determine if a tyrosine kinase inhibitor drug-free interval strategy was non-inferior to a conventional conti
Autor:
Kara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, David A Cairns, Anna Hockaday, Sergio Quezada, Mark Drayson, Martin Kaiser, Roger Owen, Holger W Auner, Gordon Cook, David Meads, Catherine Olivier, Lorna Barnard, Rhiannon Lambkin, Andrea Paterson, Bryony Dawkins, Mike Chapman, Guy Pratt, Rakesh Popat, Graham Jackson, Ceri Bygrave, Jonathan Sive, Ruth de Tute, Andrew Chantry, Christopher Parrish, Mark Cook, Samir Asher, Kwee Yong
Peer reviewed: True
INTRODUCTION: Multiple myeloma is a plasma cell malignancy that accounts for 1%-2% of newly diagnosed cancers.At diagnosis, approximately 20% of patients can be identified, using cytogenetics, to have inferior survival (high-
INTRODUCTION: Multiple myeloma is a plasma cell malignancy that accounts for 1%-2% of newly diagnosed cancers.At diagnosis, approximately 20% of patients can be identified, using cytogenetics, to have inferior survival (high-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c024a36191c37f158c659ee1de789437
https://www.repository.cam.ac.uk/handle/1810/343534
https://www.repository.cam.ac.uk/handle/1810/343534
Autor:
Amy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, David A Cairns, Anna Hockaday, Jennifer Bird, Stella Bowcock, Martin Kaiser, Ruth de Tute, Neil Rabin, Kevin Boyd, John Jones, Christopher Parrish, Hayley Gardner, David Meads, Bryony Dawkins, Catherine Olivier, Rowena Henderson, Phillip Best, Roger Owen, Matthew Jenner, Bhuvan Kishore, Mark Drayson, Graham Jackson, Gordon Cook
IntroductionMultiple myeloma is a bone marrow cancer, which predominantly affects older people. The incidence is increasing in an ageing population.Over the last 10 years, patient outcomes have improved. However, this is less apparent in older, less
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e0f7297161c69eec391d9621eca97f
https://eprints.whiterose.ac.uk/187658/1/e056147.full.pdf
https://eprints.whiterose.ac.uk/187658/1/e056147.full.pdf
Autor:
Samir Asher, Sian Faustini, Andrea paterson, Kara-Louise Royle, Amy Coulson, Lorna Barnard, Aleena Liaquat, Doina Levinte, Anna Hockaday, Catherine Olivier, David Cairns, Christopher Parrish, Gordon Cook, Graham Jackson, Michael Chapman, Martin Kaiser, Matthew Jenner, Ceri Bygrave, Jonathan Sive, Rakesh Popat, Guy Pratt, Alex Richter, Mark Drayson, Karthik Ramasamy, Kwee Yong
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S148-S149
Autor:
David A Cairns, Kara-Louise Royle
Publikováno v:
Diagnostic and Prognostic Research, Vol 5, Iss 1, Pp 1-14 (2021)
Diagnostic and Prognostic Research
Diagnostic and Prognostic Research
Background The United Kingdom Myeloma Research Alliance (UK-MRA) Myeloma Risk Profile is a prognostic model for overall survival. It was trained and tested on clinical trial data, aiming to improve the stratification of transplant ineligible (TNE) pa